Bladder cancer, Transitional cell cancer
Results
Phase 2/3
This trial looked at lapatinib for advanced bladder cancer. It was for people:
with transitional cell cancer (TCC) of the lining of the urinary system ()
whose cancer had large amounts of 2 proteins called HER1 or
Cancer Research UK supported this trial.
Recruitment start: 27 January 2009
Recruitment end: 15 January 2014
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Thomas Powles
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
GlaxoSmithKline (GSK)
NIHR Clinical Research Network: Cancer
Queen Mary University of London
This is Cancer Research UK trial number CRUKE/09/002.
Last reviewed: 4 July 2017
CRUK internal database number: 1854
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
